Effects of Development on Olanzapine-Associated Adverse Events
WOODS SW, MARTIN A, SPECTOR SG, MCGLASHAN TH. Effects of Development on Olanzapine-Associated Adverse Events. Journal Of The American Academy Of Child & Adolescent Psychiatry 2002, 41: 1439-1446. PMID: 12447030, DOI: 10.1097/00004583-200212000-00015.Peer-Reviewed Original ResearchConceptsLiver function abnormalitiesAdverse eventsFunction abnormalitiesAtypical antipsychoticsComplaint riskWeight gainAtypical antipsychotic medicationsExtrapyramidal syndromeTardive dyskinesiaProlactin increaseAntipsychotic medicationAdolescent patientsRisk ratioPatient exposureSurveillance databaseAge groupsOlanzapineComplaintsConfidence intervalsExposure estimatesAntipsychoticsSedationPatientsChildrenAdultsRisperidone in Children with Autism and Serious Behavioral Problems
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal Of Medicine 2002, 347: 314-321. PMID: 12151468, DOI: 10.1056/nejmoa013171.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementAtypical antipsychotic agentsPlacebo groupSelf-injurious behaviorRisperidone groupAntipsychotic agentsAutistic disorderIrritability scoresDouble-blind trialPrimary outcome measureTreatment of adultsTraditional antipsychotic medicationsPercent decreaseSerious behavioral disturbancesAberrant Behavior ChecklistRisperidone therapyTardive dyskinesiaAntipsychotic medicationAverage weight gainOutcome measuresPositive responsePostsynaptic dopamineSerotonin receptorsBehavioral disturbancesSevere tantrums